Featured Research

from universities, journals, and other organizations

New Drug Combination May Prevent Dangerous Complication Of Bone Marrow Transplantation

Date:
December 12, 2002
Source:
Dana-Farber Cancer Institute
Summary:
A three-drug therapy, which includes a novel medication called sirolimus, reduces graft-versus-host disease (GVHD) in stem cell transplant patients more effectively and with less toxicity than traditional treatments, an ongoing clinical study by Dana-Farber Cancer Institute scientists suggests.

PHILADELPHIA -- A three-drug therapy, which includes a novel medication called sirolimus, reduces graft-versus-host disease (GVHD) in stem cell transplant patients more effectively and with less toxicity than traditional treatments, an ongoing clinical study by Dana-Farber Cancer Institute scientists suggests.

Related Articles


Interim results of the trial, which began two years ago, will be presented by researchers at the annual meeting of the American Society of Hematology in Philadelphia (Dec. 9, 4 p.m., Room 204).

The study seeks to produce better outcomes for patients receiving stem cell transplants for diseases such as leukemia and lymphoma. Such patients are at risk for GVHD, a condition in which transplanted immune cells mount an attack on patients' own tissue and organs. The drugs tacrolimus and methotrexate, though offering moderate control of GVHD, are associated with side effects such as kidney failure, high blood pressure, mouth sores, liver damage, and lowered white blood cell counts.

"These are very exciting early data," says the study's lead author, Joseph Antin, MD, of Dana-Farber. "We have been looking for ways of reducing transplant-related side effects for many years and these data tell us that we are on the right track. We are proceeding with further studies designed to eliminate methotrexate entirely while continuing to reduce toxicity and control GVHD."

Because sirolimus – a medication that interferes with the signaling mechanism in immune system cells – has been shown to work "synergistically" with tacrolimus, researchers theorized that low doses of the two drugs, in combination with methotrexate, might provide more effective control of GVHD with fewer side effects.

The 41-patient study is bearing out those hopes. Whereas 30 percent of unrelated donor transplant patients would normally be expected to develop severe GVHD, only 13 percent of the patients in the study have incurred that level of GVHD. The therapy produced no unusual side effects and patients' blood counts reached adequate levels.

Dana-Farber Cancer Institute (http://www.danafarber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.


Story Source:

The above story is based on materials provided by Dana-Farber Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Dana-Farber Cancer Institute. "New Drug Combination May Prevent Dangerous Complication Of Bone Marrow Transplantation." ScienceDaily. ScienceDaily, 12 December 2002. <www.sciencedaily.com/releases/2002/12/021212080856.htm>.
Dana-Farber Cancer Institute. (2002, December 12). New Drug Combination May Prevent Dangerous Complication Of Bone Marrow Transplantation. ScienceDaily. Retrieved April 21, 2015 from www.sciencedaily.com/releases/2002/12/021212080856.htm
Dana-Farber Cancer Institute. "New Drug Combination May Prevent Dangerous Complication Of Bone Marrow Transplantation." ScienceDaily. www.sciencedaily.com/releases/2002/12/021212080856.htm (accessed April 21, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, April 21, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Humanoid Robot Can Recognise and Interact With People

Humanoid Robot Can Recognise and Interact With People

Reuters - Innovations Video Online (Apr. 20, 2015) An ultra-realistic humanoid robot called &apos;Han&apos; recognises and interprets people&apos;s facial expressions and can even hold simple conversations. Developers Hanson Robotics hope androids like Han could have uses in hospitality and health care industries where face-to-face communication is vital. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Labour Party Warns Britain's Health Service 'on Life Support'

Labour Party Warns Britain's Health Service 'on Life Support'

AFP (Apr. 20, 2015) Britain&apos;s opposition Labour Party Monday claimed the National Health Service (NHS) was &apos;on life support&apos; as it turned its attention to the state-run service, which is a key issue for the UK&apos;s May 7 general election. Video provided by AFP
Powered by NewsLook.com
Sierra Leone Students Back to School After Long Ebola Closure

Sierra Leone Students Back to School After Long Ebola Closure

Reuters - News Video Online (Apr. 20, 2015) After an eight-month break, children in Sierra Leone return to school for the first time since the beginning of the Ebola outbreak. Nathan Frandino reports. Video provided by Reuters
Powered by NewsLook.com
Teen E-Cigarette Use Triples, Government Debates Regulations

Teen E-Cigarette Use Triples, Government Debates Regulations

Newsy (Apr. 19, 2015) The Centers for Disease Control and Prevention says in 2014, 13.4 percent of high school students reported smoking an e-cigarette within 30 days. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins